Clinical Trial Update: Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of lisocabtagene maraleucel for minimal residual disease in patients with Large B-cell Lymphoma. The trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Large B-cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING